Background: We evaluated maternal CD4+ cell count (CD4+) decline after PMTCT prophylaxis in a multi-country HIV care program.
Introduction
In resource-limited countries HIV-infected pregnant women not yet eligible for antiretroviral treatment (ART) typically receive short-course antiretroviral (ARV) prophylaxis [1] for the prevention of mother-to-child transmission. In July 2010, the World Health Organization (WHO) proposed new guidelines for the use of ARV drugs for treating pregnant women and preventing HIV infection in infants. Two options of similar efficacy are now offered for women with a CD4+ cell count (CD4+) .350 cells/mm 3 , the current immunologic eligibility threshold for initiating ART [2] : Option A, zidovudine (AZT) during pregnancy plus single-dose nevirapine (sd-NVP) at delivery and daily NVP prophylaxis to the infant during breast feeding or Option B, triple ARV prophylaxis (tARVp) starting at 14 weeks of gestation until cessation of all breastfeeding [2] . Despite widespread scale-up of these new guidelines, the impact of stopping prolonged maternal tARVp among women with high CD4+ is not well described with inconsistent results across studies [3, 4] . Furthermore, in non-pregnant HIV-infected adults, structured interruption of treatment significantly increases the risk of opportunistic disease or death in patients eligible for ART [5, 6] , raising the possibility that tARVp may lead to suboptimal long-term outcomes compared to other forms of prophylaxis.
The objective of this analysis was to describe CD4+ decline after discontinuation of ARV prophylaxis post-delivery among HIVinfected women not eligible for ART in a large, multi-country cohort of HIV-infected pregnant women and to compare whether this decline varied by PMTCT regimen.
Methods

Study Design and Setting
The MTCT-Plus Initiative provided support to 13 clinical programs in eight countries in sub-Saharan Africa (Cameroon, Côte d'Ivoire, Kenya, Mozambique, Rwanda, South Africa, Uganda, and Zambia) and in Thailand to implement HIV/AIDS care and treatment to families identified through PMTCT services [7] . Pregnant or recently postpartum women identified as HIVinfected (HIV+) in PMTCT programs were invited to enroll in the MTCT-Plus Initiative which was built upon existing services and provided HIV-infected women, their partners, and their children, holistic family care with unrestricted access to ART for eligible patients [8, 9] .
ART eligibility was based on WHO and national guidelines in effect at the time. Prior ART-naïve pregnant women who were not eligible for ART, received an ARV prophylaxis regimen, had a CD4+ prior to or within 30 days of delivery $250 cells/mm 3 and had at least one CD4+ after delivery were included in this analysis. Women receiving ART during pregnancy, or who had CD4+ ,250 cells/ mm 3 at enrollment or who had no ARV prophylaxis or missing documentation of ARV prophylaxis were excluded.
Enrollment and Follow-up
The MTCT-Plus Initiative procedures for enrollment and follow-up have been previously described [8] [9] [10] . In brief, pregnant women received CD4+ cell count at enrollment and maternal clinical and socio-demographic characteristics were recorded. HIV-infected women not eligible for ART were scheduled to attend follow-up visits every three months for the first six months following enrollment then every six months thereafter for clinical examination, WHO staging and CD4+ monitoring.
Antiretroviral Prophylaxis for PMTCT
MTCT-Plus Initiative sites followed local guidelines for PMTCT prophylactic regimens. Initially, most programs offered a sd-NVP regimen. By 2004, sites in Bangkok, Thailand, and Eldoret, Kenya, offered triple-drug ARV prophylaxis (tARVp) consisting of zidovudine (AZT) + lamivudine (3TC) + NVP or nelfinavir (NFV) prophylaxis during pregnancy. Over time most sites offered short-course (sc-ARVp) multidrug PMTCT regimens (antepartum AZT with or without 3TC + intrapartum sd-NVP). All ARV prophylaxis initiated antepartum or intrapartum was discontinued after delivery, as per WHO guidelines [1] including tARVp in women not eligible for ART.
Outcomes
The primary outcome, CD4+ decline, was defined as: 1) the 12 and 24 month cumulative probability from delivery (time when ARV prophylaxis was discontinued) to decline in CD4+ to ,200 cells/mm 3 
Statistical Analysis
Group comparisons were conducted using Student's t-test or non-parametric Kruskal-Wallis test for continuous variables and the Chi square test or Fisher's exact test for categorical variables. Kaplan-Meier plots were used to estimate the cumulative probability of reaching outcome. Time was measured from the date of delivery and we right-censored women who were lost-tofollow-up (LTF), (.6 months since last scheduled visit), died, withdrew or were without an event at the date of their last clinical visit or March 31, 2008 when data collection ended. In addition, women who started ART after delivery were censored at the date ART was prescribed. The Log-Rank test was used to compare the probability of CD4+ decline to ,200 cells/mm 3 or ,350 cells/ mm 3 between the three ARV prophylaxis groups (sd-NVP, scARVp, and tARVp). We used Weibull regression models to identify risk factors for reaching the criteria for ART eligibility at 24 months. The following variables were considered: ARV prophylaxis regimen, age, CD4+ and WHO stage at enrollment. All factors associated with the outcomes at a p-value ,0.25 were included in the multivariable analysis. Adjusted hazard ratios (aHR) and their 95% confidence interval (CI) are reported with two-sided p-values. The effect of program site was evaluated using Kaplan-Meier plots and associated Log-Rank tests independently for each ARV prophylaxis regimen. All analyses were performed in intent-to-treat and on-treatment population with SAS software version 9.2 (SAS Institute, Cary, NC, USA).
Ethics Statement
The conduct of the MTCT-Plus Initiative as a service delivery program with data collection for monitoring and evaluation purposes was approved by Columbia University's Institutional Review Board and local ethics review boards in each country where the study was implemented.
Results
Enrollment Characteristics
Between January 2003 and December 2007, a total of 3,825 HIV-infected pregnant women were enrolled and among them 1,284 initiated ART during pregnancy, 366 had enrollment CD4+ ,250 mm 3 but did not initiate ART and 440 had no CD4+ measurements recorded. After excluding women with only a single CD4+ measure (n = 152) or missing documentation of PMTCT regimen (n = 190), 1,393 women met inclusion criteria for this analysis with enrollment CD4+ $250 cells/mm 3 . Among these women a subset (n = 903) also met criteria of CD4+ $400 cells/ mm 3 ( Figure 1 The median follow-up from enrollment among 1,393 women with CD4+ $250 cells/mm 3 was 27.2 months (IQR: 15.6-41.7) and the median duration of antepartum ARV prophylaxis was 6 weeks (IQR: 4-9), with similar duration for tARVp and Additional analyses examined whether there were significant site differences in the proportion of women reaching CD4 decline ,350 cells/mm 3 endpoint (Table S2 ). The proportion of women reaching ,350 cells/mm 3 at 24 months post enrollment was similar among women receiving sc-ARVp in Thailand compared to women receiving the same regimen in other sites. Similarly, the proportion of women reaching ,350 cells/mm 3 at 24 months post enrollment was similar among women receiving sd-NVP in Eldoret compared to other sites.
Multivariate Analysis
Factors associated with CD4+ decline to either ,200 cells/ mm 3 or ,350 cells/mm 3 were similar. In adjusted models, ARV prophylaxis regimen, age and enrollment CD4+ were significantly and independently associated with CD4+ decline to ,200 cells/ mm 3 and CD4+ decline to ,350 cells/mm 3 ( Table 2 ). Higher CD4+ cell count at enrollment was associated with a reduced probability of immunologic decline to endpoint: for each increase of 100 cells/mm 3 , the probability of CD4+ decline was reduced by 40% for CD4+,200 cells/mm 3 
Discussion
We examined CD4+ decline among women not yet eligible for ART who received ARV prophylaxis during pregnancy through delivery in the MTCT-Plus Initiative, a multicountry HIV care and treatment program. Within the first 24 months postpartum, 11.6% of women had a CD4+ decline to ,200 cells/mm 3 . This figure more than doubled to 27.5% of women with CD4+ decline meeting current ART eligibility thresholds (,350 cells/mm 3 ). The finding that one in four HIV-infected women who received ARV prophylaxis during pregnancy/delivery become eligible for ART within 24 months of delivery has profound implications for efforts to eliminate perinatal transmission and improve maternal health [11] . The large number of women who experienced CD4+ decline to ART eligibility thresholds and the speed of this decline underscores the urgent need to engage, and retain HIV-infected women identified during pregnancy in ongoing HIV care and treatment with post-partum CD4+ monitoring a critical component of clinical care. In addition, lower enrollment CD4+ cell count (,500 cells/mm 3 ) was associated with a higher risk of CD4+ decline, suggesting that these women may benefit from initiation of therapeutic ART during pregnancy rather than prophylaxis.
Several studies have examined CD4+ decline following PMTCT prophylaxis but findings have been inconsistent and difficult to compare due to varying lengths of follow-up, variety of ARV prophylactic regimens and differences in health status at the ) who initiated tARVp had CD4+ decline to ,300 cells/mm 3 within 24 months after discontinuing prophylaxis [12] . Comparisons of CD4+ decline among women who either discontinued tARVp at delivery or continued have yielded conflicting results: over a short followup period of 6 months postpartum, women who discontinued tARVp had a higher rate of decline compared to women who continued ART regimens in a Brazilian cohort [13] . In contrast, Watts and colleagues in the US found no difference in the rate of decline in CD4+ over a longer follow-up period, 12 months postpartum, among women who discontinued prophylaxis compared to those who continued regimens, even after stratifying by prophylaxis regimen (scARVp or AZT monotherapy). Neither study reported CD4+ decline using ART-eligibility end points and thus cannot be directly compared to our results. However, data from AIDS Clinical Trials Group 5170 suggest that CD4+ decline following ARV discontinuation is relatively slow with postpartum women losing an average of 12 CD4+ cells per month after stopping tARVp [4] .
This analysis noted that CD4+ during pregnancy was independently associated with CD4+ decline. Women with lower CD4+ at enrollment were more likely to have CD4+ decline to ARTeligibility thresholds. Several recent follow-up studies of disease progression among healthy participants in randomized PMTCT clinical trials in Sub-Saharan Africa have similarly found that CD4+ cell count ,500 during pregnancy was associated with a significantly higher risk of decline to CD4,350 threshold within 12-18 months after cessation of ARV prophylaxis [3, 14] . The Kesho Bora trial evaluated CD4+ decline after discontinuation of tARVp or sc-ARVp in women with pregnancy CD4+ between 200 and 500 cells/mm 3 . Consistent with our results, CD4+ at time of antiretroviral prophylaxis initiation was independently and significantly associated with overall disease progression [3] .
Among women with pregnancy CD4+ ,500, 20% had a CD4+ decline to ,350 threshold within 12 months of delivery, and almost half of this group met ART threshold by 24 months postpartum. The rapid disease progression in women with lower CD4+ observed in the MTCT-Plus Initiative and HPTN 046 [14] cohorts provides additional evidence of potential benefit of initiating lifelong ART among pregnant women at higher CD4+ than currently recommended [1] . Several countries in SubSaharan Africa are considering new approaches to PMTCT including initiating all pregnant women on lifelong ART to optimize maternal health, prevent infant transmissions, and reduce sexual transmission within discordant partnerships [15, 16] . Initiating ART at higher CD4 threshold for pregnant women would also avoid the potential increased risk of opportunistic diseases or death noted in structured treatment interruption among adults [5, 6] . Although discontinuation of ARV prophylaxis after delivery is not equivalent to structured treatment interruption [5, 6] , in sub-Saharan Africa where the incidence of pregnancy among HIV-infected women is relatively high (7.8/100 womenyears) and the rate of re-initiation of ARV prophylaxis is likely to be high as well, the clinical implications may be similar [8] . In our study, it was reassuring that we observed relatively little clinical disease progression during the postpartum observation period.
PMTCT regimen was independently associated with CD4+ decline with both triple ARV prophylaxis and sd-NVP regimens associated with two-fold increase in CD4+ decline compared to short-course PMTCT after adjusting for pregnancy CD4+ and WHO clinical stage, maternal age and site. One potential explanation for this finding was differential loss to follow-up (LTF) among the three regimen groups. Although the sd-NVP and tARVp regimen groups had higher LTF rates compared to the scARVp group, we found no differences in CD4+ or WHO staging at enrollment between women lost to follow-up by 24 months and women who remained in follow-up and did not experience decline to CD4+ ,350 decline either in the total sample, or within regimen groups. Therefore, we believe that differential losses to follow-up among healthier women is not the likely explanation for our findings. It should be noted that the overall LTF rate (26%) in this cohort of healthy pregnant women after more than 24 months of follow-up is substantially lower than the median LTF rate (55%) reported from other pre-ART adult cohorts in Sub-Saharan Africa [17] . The mechanism through which tARVp interruption may be associated with more rapid decline of CD4+ than other PMTCT regimens are not well understood. In pregnant women, a rebound of plasma HIV-1 RNA viral load to pre-treatment levels after ARV prophylaxis interruption has been reported among women who received sc-ARVp with antepartum AZT and sd-NVP [18, 19] . In the context of tARVp, a change in plasma HIV-1 RNA viral load after tARVp discontinuation could be occurring at a higher magnitude than those after sc-ARVp discontinuation. In addition, a transient overshoot of HIV viremia after discontinuation of ART was reported and resembles the viraemic burst during primary HIV infection [20] . In adults, after an interruption of ART, individuals lost on average 20 cells/mm 3 per week in the first 8 weeks with a subsequent decrease of 2.0 cells/mm 3 per week [21] . We speculate that a similar rebound viremia may also explain CD4+ decline among women receiving intrapartum sd-NVP, which may be attenuated by several weeks of zidovudine among women receiving sc-PMTCT. Nonetheless, these findings of different outcomes by ARV prophylaxis regimen will need to be confirmed in other studies.
Strengths of this study include its relatively large sample size and long follow-up period, (median 27 months post-delivery). In addition, as the duration of ARV prophylaxis was relatively short, the CD4+ at enrollment likely reflects the CD4+ at delivery [22] when ARV is discontinued therefore allowing a comparison between the three groups. Unlike other evaluations based on clinical trial cohorts, we present more generalizable ''field efficacy'' from an HIV treatment program, thus providing important information on the rate of CD4+ decline across a varied population of women. Other strengths were that all women were prospectively followed using a standardized data collection form capturing laboratory and clinical data.
The primary limitation of our study is that the variable of interest (ARV prophylaxis regimens) was not randomized leaving open the possibility that ARV regimen group or other characteristics were not strictly comparable. Although the CD4+ at enrollment was statistically different in the three prophylaxis groups, these differences were not large or clinically meaningful. The fact that tARVp was initiated only in one site in Kenya and in Thailand among women not eligible for ART is another limitation. The decision at both of these sites to use tARVp may represent differences in drug access as well as other treatment approaches that we cannot address in this analysis. In general, we observed a consistent rate of CD4+ decline across programs sites although some sites had higher rates of sc-ARVp or sd-NVP use depending on country guidelines. Another limitation is that women in the MTCT-Plus Initiative only received prophylaxis during pregnancy, as per WHO guidelines in place at the time of the program. Therefore, tARVp was administered for a much shorter duration than currently recommended through the duration of breastfeeding [1, 2] . Also, important laboratory measures of HIV disease progression such as viral load monitoring were not available for this cohort.
In summary, our study showed a substantial proportion of women receiving ARV prophylaxis during pregnancy experienced CD4+ decline to ART-eligibility endpoints within 24 months postpartum. Baseline CD4+ significantly affected time for CD4+ progression after stopping ARV prophylaxis for PMTCT. Approximately 46% of women with baseline CD4+ between 400-499 cells/mm 3 had CD4+ decline ,350 cells/mm 3 by 24 months. Given this rapid rate of immunologic progression, these findings suggest that pregnant women with CD4+ ,500 cells/mm 3 should be considered for lifetime ART initiation. Recent findings from HPTN 052 demonstrated a 96% reduction of HIV transmission among HIV-serodiscordant couples when HIV-infected partners initiated ART when CD4+ ,500 cells/ mm 3 providing additional support for continuation of triple-drug ARV regimen for women after delivery, especially those with potential sero-discordant partners [16] . The IMPAACT network PROMISE trial (clinical trial NCT01061151) is poised to address this pressing question and, in the next several years, should be able to inform treatment and prophylaxis recommendations for pregnant women with HIV. 
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